Network pharmacology strategies toward multi-target anticancer therapies: From computational models to experimental design principles

Current Pharmaceutical Design

Volumn 20, Issue 1, 2014, Pages 23-36

  Tang, Jing ^a,b   Aittokallio, Tero ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

Author keywords

Anticancer therapies; Computational models; Experimental design; Network pharmacology

Indexed keywords

ANTINEOPLASTIC AGENT; LIGAND;

ADVERSE DRUG REACTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; COMPUTER AIDED DESIGN; DRUG COMBINATION; DRUG DATABASE; DRUG DEVELOPMENT; DRUG INTERACTION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG TARGETING; EXPERIMENTAL DESIGN; EXPERIMENTAL TEST; HIGH THROUGHPUT SCREENING; HUMAN; KNOWLEDGE BASE; KNOWLEDGE DISCOVERY; MATHEMATICAL MODEL; MOLECULARLY TARGETED THERAPY; NETWORK LEARNING; NETWORK PHARMACOLOGY; PHARMACOLOGY; PHENOTYPE; POLYPHARMACOLOGY; PREDICTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; BIOLOGY; CHEMISTRY; COMPUTER SIMULATION; REVIEW;

ANTINEOPLASTIC AGENTS; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; DRUG INTERACTIONS;

EID: 84907033076     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990470     Document Type: Article

References (178)

1. [1] Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov 2012; 11: 191-200.
2. [2] Hopkins AL. Network pharmacology: The next paradigm in drug discovery. Nat Chem Biol 2008; 4: 682-90.
3. [3] Kitano H. A robustness-based approach to systems-oriented drug design. Nat Rev Drug Discov 2007; 6: 202-10.
4. [4] Xie L, Xie L, Kinnings SL, Bourne PE. Novel computational approaches to polypharmacology as a means to define responses to individual drugs. Annu Rev Pharmacol Toxicol 2012; 52: 361-79.
5. [5] Lehár J, Krueger AS, Avery W, et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol 2009; 27: 659-66.
6. [6] Lackner MR, Wilson TR, Settleman J. Mechanisms of acquired resistance to targeted cancer therapies. Future Oncol 2012; 8: 999-1014.
7. [7] Ramaswamy S. Rational design of cancer-drug combinations. N Engl J Med 2007; 357: 299-300.
8. [8] Ashworth A, Lord CJ, Reis-Filho JS. Genetic interactions in cancer progression and treatment. Cell 2011; 145: 30-8.
9. [9] Pe’er D, Hacohen N. Principles and strategies for developing network models in cancer. Cell 2011; 144: 864-73.
10. [10] Aittokallio T, Schwikowski B. Graph-based methods for analysing networks in cell biology. Brief Bioinform 2006; 7: 243-55.
11. [11] Vidal M, Cusick ME, Barabási A-L. Interactome networks and human disease. Cell 2011; 144: 986-98.
12. [12] Schadt EE. Molecular networks as sensors and drivers of common human diseases. Nature 2009; 461: 218-23.
13. [13] Del Sol A, Balling R, Hood L, Galas D. Diseases as network perturbations. Curr Opin Biotechnol 2010; 21: 566-71.
14. [14] Chuang H-Y, Hofree M, Ideker T. A decade of systems biology. Annu Rev Cell Dev Biol 2010; 26: 721-44.
15. [15] Liu Z-P, Wang Y, Zhang X-S, Chen L. Network-based analysis of complex diseases. IET Syst Biol 2012; 6: 22-33.
16. [16] Barabási A-L, Oltvai ZN. Network biology: Understanding the cell’s functional organization. Nat Rev Genet 2004; 5: 101-13.
17. [17] Barabási A-L, Gulbahce N, Loscalzo J. Network medicine: A network-based approach to human disease. Nat Rev Genet 2011; 12: 56-68.
18. [18] Schadt EE, Friend SH, Shaywitz DA. A network view of disease and compound screening. Nat Rev Drug Discov 2009; 8: 286-95.
19. [19] Zanzoni A, Soler-López M, Aloy P. A network medicine approach to human disease. FEBS Lett 2009; 583: 1759-65.
20. [20] Pawson T, Linding R. Network medicine. FEBS Lett 2008; 582: 1266-70.
21. [21] Creixell P, Schoof EM, Erler JT, Linding R. Navigating cancer network attractors for tumor-specific therapy. Nat Biotechnol 2012; 30: 842-8.
22. [22] Leung EL, Cao Z-W, Jiang Z-H, Zhou H, Liu L. Network-based drug discovery by integrating systems biology and computational technologies. Brief Bioinform 2012; doi: 10.1093/bib/bbs043.
23. [23] Pujol A, Mosca R, Farrés J, Aloy P. Unveiling the role of network and systems biology in drug discovery. Trends Pharmacol Sci 2010; 31: 115-23.
24. [24] Wist AD, Berger SI, Iyengar R. Systems pharmacology and genome medicine: A future perspective. Genome Med 2009; 1: 11.
25. [25] Arrell DK, Terzic A. Network systems biology for drug discovery. Clin Pharmacol Ther 2010; 88: 120-5.
26. [26] Boran ADW, Iyengar R. Systems approaches to polypharmacology and drug discovery. Curr Opin Drug Discov Devel 2010; 13: 297-309.
27. [27] Berger SI, Iyengar R. Network analyses in systems pharmacology. Bioinformatics 2009; 25: 2466-72.
28. [28] Zhao S, Iyengar R. Systems pharmacology: Network analysis to identify multiscale mechanisms of drug action. Annu Rev Pharmacol Toxicol 2012; 52: 505-21.
29. [29] Woollard PM, Mehta NAL, Vamathevan JJ, Van Horn S, Bonde BK, Dow DJ. The application of next-generation sequencing technologies to drug discovery and development. Drug Discov Today 2011; 16: 512-9.
30. [30] Cheng T, Li Q, Zhou Z, Wang Y, Bryant SH. Structure-Based Virtual Screening for Drug Discovery: A Problem-Centric Review. AAPS J 2012; 14: 133-41.
31. [31] Lee MJ, Ye AS, Gardino AK, et al. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 2012; 149: 780-94.
32. [32] Capobianco E. Dynamic networks in systems medicine. Front Genet 2012; 3: 185.
33. [33] Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: A looking glass for cancer? Nat Rev Cancer 2012; 12: 323-34.
34. [34] Gillies RJ, Verduzco D, Gatenby RA. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer 2012; 12: 487-93.
35. [35] Rostami-Hodjegan A, Tucker GT. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 2007; 6: 140-8.
36. [36] Yoon M, Campbell JL, Andersen ME, Clewell HJ. Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results. Crit Rev Toxicol 2012; 42: 633-52.
37. [37] Venkatakrishnan K, Pickard MD, Von Moltke LL. A quantitative framework and strategies for management and evaluation of metabolic drug-drug interactions in oncology drug development: New molecular entities as object drugs. Clin Pharmacokinet 2010; 49: 703-27.
38. [38] Dancey JE, Chen HX. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov 2006; 5: 649-59.
39. [39] Zimmermann GR, Lehár J, Keith CT. Multi-target therapeutics: When the whole is greater than the sum of the parts. Drug Discov Today 2007; 12: 34-42.
40. [40] Jia J, Zhu F, Ma X, Cao ZW, Li YX, Chen YZ. Mechanisms of drug combinations: Interaction and network perspectives. Nat Rev Drug Discov 2009; 8: 111-28.
41. [41] Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 2012; 30: 679-92.
42. [42] Koutsoukas A, Simms B, Kirchmair J, et al. From in silico target prediction to multi-target drug design: Current databases, methods and applications. J of Proteomics 2011; 74: 2554-74.
43. [43] Azmi AS, Eds. Systems biology in cancer research and drug discovery. 2012th ed. Dordrecht: Springer 2012.
44. [44] Cong F, Cheung AK, Huang S-MA. Chemical genetics-based target identification in drug discovery. Annu Rev Pharmacol Toxicol 2012; 52: 57-78.
45. [45] Ong S-E, Li X, Schenone M, Schreiber SL, Carr SA. Identifying cellular targets of small-molecule probes and drugs with biochemical enrichment and SILAC. Methods Mol Biol 2012; 803: 129-40.
46. [46] Zhang C, Habets G, Bollag G. Interrogating the kinome. Nat Biotechnol 2011; 29: 981-3.
47. [47] Gleeson MP, Hersey A, Montanari D, Overington J. Probing the links between in vitro potency, ADMET and physicochemical parameters. Nat Rev Drug Discov 2011; 10: 197-208.
48. [48] Li X, Hu Y. Identifying the cellular targets of bioactive small molecules with activity-based probes. Curr Med Chem 2010; 17: 3030-44.
49. [49] Butcher RA, Schreiber SL. Using genome-wide transcriptional profiling to elucidate small-molecule mechanism. Curr Opin Chem Biol 2005; 9: 25-30.
50. [50] Schirle M, Bantscheff M, Kuster B. Mass spectrometry-based proteomics in preclinical drug discovery. Chem Biol 2012; 19: 72-84.
51. [51] Klipp E, Wade RC, Kummer U. Biochemical network-based drugtarget prediction. Curr Opin Biotechnol 2010; 21: 511-6.
52. [52] Brown RD, Martin YC. Use of structure_activity data to compare structure-based clustering methods and descriptors for use in compound selection. J Chem Inf Comput Sci 1996; 36: 572-84.
53. [53] Spowage BM, Bruce CL, Hirst JD. Interpretable correlation descriptors for quantitative structure-activity relationships. J Cheminform 2009; 1: 22.
54. [54] Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, Shoichet BK. Relating protein pharmacology by ligand chemistry. Nat Biotechnol 2007; 25: 197-206.
55. [55] Pearson WR. Empirical statistical estimates for sequence similarity searches. J Mol Biol 1998; 276: 71-84.
56. [56] Gregori-Puigjané E, Setola V, Hert J, et al. Identifying mechanismof-action targets for drugs and probes. Proc Natl Acad Sci USA 2012; 109: 11178-83.
57. [57] MDL Information Systems, Inc. The MDL drug data report database [Internet]. Available from: Www.mdli.com
58. [58] Olah M, Rad R, Ostopovici L, et al. WOMBAT and WOMBATPK: Bioactivity databases for lead and drug discovery. In: Schreiber SL, Kapoor P, Wess G, Eds. In chemical biology: From small molecules to systems biology and drug design. New York: Wiley-VCH; 2007; pp. 760-86.
59. [59] Hert J, Keiser MJ, Irwin JJ, Oprea TI, Shoichet BK. Quantifying the relationships among drug classes. J Chem Inf Model 2008; 48: 755-65.
60. [60] Ekins S, Mestres J, Testa B. In silico pharmacology for drug discovery: Methods for virtual ligand screening and profiling. Br. J Pharmacol 2007; 152: 9-20.
61. [61] Liu T, Lin Y, Wen X, Jorissen RN, Gilson MK. BindingDB: A web-accessible database of experimentally determined proteinligand binding affinities. Nucleic Acids Res 2007; 35: D198-201.
62. [62] Diller DJ. The synergy between combinatorial chemistry and highthroughput screening. Curr Opin Drug Discov Devel 2008; 11: 346-55.
63. [63] Goh CS, Bogan AA, Joachimiak M, Walther D, Cohen FE. Coevolution of proteins with their interaction partners. J Mol Biol 2000; 299: 283-93.
64. [64] Surade S, Blundell TL. Structural biology and drug discovery of difficult targets: The limits of ligandability. Chem Biol 2012; 19: 42-50.
65. [65] Whisstock JC, Lesk AM. Prediction of protein function from protein sequence and structure. Q Rev Biophys 2003; 36: 307-40.
66. [66] Singh S, Malik BK, Sharma DK. Molecular drug targets and structure based drug design: A holistic approach. Bioinformation 2006; 1: 314-20.
67. [67] Ben-Hur A, Noble WS. Kernel methods for predicting proteinprotein interactions. Bioinformatics 2005; 21: I38-46.
68. [68] Gönen M. Predicting drug-target interactions from chemical and genomic kernels using Bayesian matrix factorization. Bioinformatics 2012; 28: 2304-10.
69. [69] Li Q, Lai L. Prediction of potential drug targets based on simple sequence properties. BMC Bioinformatics 2007; 8: 353.
70. [70] Yamanishi Y, Araki M, Gutteridge A, Honda W, Kanehisa M. Prediction of drug-target interaction networks from the integration of chemical and genomic spaces. Bioinformatics 2008; 24: I232-40.
71. [71] Yildirim MA, Goh K-I, Cusick ME, Barabási AL, Vidal M. Drugtarget network. Nat Biotechnol 2007; 25: 1119-26.
72. [72] He Z, Zhang J, Shi XH, et al. Predicting drug-target interaction networks based on functional groups and biological features. PLoS One 2010; 5: E9603
73. [73] Cheng AC, Coleman RG, Smyth KT, et al. Structure-based maximal affinity model predicts small-molecule druggability. Nat Biotechnol 2007; 25: 71-5.
74. [74] Brooijmans N. Docking methods, ligand design, and validation data sets in the structural genomics era. In: Gu J, Bourne PE. Eds. Structural bioinformatics. 2nd ed. New York: Wiley-Blackwell 2009; pp. 635-63.
75. [75] Laurie ATR, Jackson RM. Methods for the prediction of proteinligand binding sites for structure-based drug design and virtual ligand screening. Curr Protein Pept Sci 2006; 7: 395-406.
76. [76] Xie L, Xie L, Bourne PE. Structure-based systems biology for analyzing off-target binding. Curr Opin Struct Biol 2011; 21: 189-99.
77. [77] Lamb J. The Connectivity Map: A new tool for biomedical research. Nat Rev Cancer 2007; 7: 54-60.
78. [78] Iorio F, Bosotti R, Scacheri E, et al. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci USA 2010; 107: 14621-6.
79. [79] Barrett T, Troup DB, Wilhite SE, et al. NCBI GEO: Archive for functional genomics data sets--10 years on. Nucleic Acids Res 2010; 39: D1005-10.
80. [80] Hassane DC, Guzman ML, Corbett C, et al. Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood 2008; 111: 5654-62.
81. [81] Sleno L, Emili A. Proteomic methods for drug target discovery. Curr Opin Chem Biol 2008; 12: 46-54.
82. [82] Chen B, McConnell KJ, Wale N, Wild DJ, Gifford EM. Comparing bioassay response and similarity ensemble approaches to probing protein pharmacology. Bioinformatics 2011; 27: 3044-9.
83. [83] Fliri AF, Loging WT, Thadeio PF, Volkmann RA. Analysis of drug-induced effect patterns to link structure and side effects of medicines. Nat Chem Biol 2005; 1: 389-97.
84. [84] Campillos M, Kuhn M, Gavin A-C, Jensen LJ, Bork P. Drug target identification using side-effect similarity. Science 2008; 321: 263-6.
85. [85] Terstappen GC, Schlüpen C, Raggiaschi R, Gaviraghi G. Target deconvolution strategies in drug discovery. Nat Rev Drug Discov 2007; 6: 891-903.
86. [86] Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 2010; 10: 130-7.
87. [87] Kumar N, Hendriks BS, Janes KA, De Graaf D, Lauffenburger DA. Applying computational modeling to drug discovery and development. Drug Discov Today 2006; 11: 806-11.
88. [88] Cirit M, Haugh JM. Quantitative models of signal transduction networks: How detailed should they be? Commun Integr Biol 2011; 4: 353-6.
89. [89] Birtwistle MR, Hatakeyama M, Yumoto N, Ogunnaike BA, Hoek JB, Kholodenko BN. Ligand-dependent responses of the ErbB signaling network: Experimental and modeling analyses. Mol Syst Biol 2007; 3: 144.
90. [90] Hendriks BS, Cook J, Burke JM, Beusmans JM, Lauffenburger DA, De Graaf D. Computational modelling of ErbB family phosphorylation dynamics in response to transforming growth factor alpha and heregulin indicates spatial compartmentation of phosphatase activity. Syst Biol (Stevenage) 2006; 153: 22-33.
91. [91] Samaga R, Saez-Rodriguez J, Alexopoulos LG, Sorger PK, Klamt S. The logic of EGFR/ErbB signaling: Theoretical properties and analysis of high-throughput data. PLoS Comput Biol 2009; 5: E1000438.
92. [92] Sahin O, Fröhlich H, Löbke C, et al. Modeling ERBB receptorregulated G1/S transition to find novel targets for de novo trastuzumab resistance. BMC Syst Biol 2009; 3: 1.
93. [93] Morris MK, Shriver Z, Sasisekharan R, Lauffenburger DA. Querying quantitative logic models (Q2LM) to study intracellular signaling networks and cell-cytokine interactions. Biotechnol J 2012; 7: 374-86.
94. [94] Friedman N. Inferring Cellular Networks Using Probabilistic Graphical Models. Science. 2004; 303: 799-805.
95. [95] Blair RH, Trichler DL, Gaille DP. Mathematical and statistical modeling in cancer systems biology. Front Physiol 2012; 3: 227.
96. [96] Yörük E, Ochs MF, Geman D, Younes L. A comprehensive statistical model for cell signaling. IEEE/ACM Trans Comput Biol Bioinform 2011; 8: 592-606.
97. [97] Zhu M, Zhang H, Humphreys WG. Drug metabolite profiling and identification by high-resolution mass spectrometry. J Biol Chem 2011; 286: 25419-25.
98. [98] Kim HU, Sohn SB, Lee SY. Metabolic network modeling and simulation for drug targeting and discovery. Biotechnol J 2012; 7: 330-42.
99. [99] Duarte NC, Becker SA, Jamshidi N, et al. Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proc Natl Acad Sci USA 2007; 104: 1777-82.
100. [100] Hao T, Ma H-W, Zhao X-M, Goryanin I. Compartmentalization of the Edinburgh Human Metabolic Network. BMC Bioinformatics 2010; 11: 393.
101. [101] Romero P, Wagg J, Green ML, Kaiser D, Krummenacker M, Karp PD. Computational prediction of human metabolic pathways from the complete human genome. Genome Biol 2005; 6: R2.
102. [102] Karp PD, Riley M, Paley SM, Pellegrini-Toole A. The MetaCyc database. Nucleic Acids Res 2002; 30: 59-61.
103. [103] Stobbe MD, Houten SM, Jansen GA, Van Kampen AH, Moerland PD. Critical assessment of human metabolic pathway databases: A stepping stone for future integration. BMC Syst Biol 2011; 5: 165.
104. [104] Agren R, Bordel S, Mardinoglu A, Pornputtapong N, Nookaew I, Nielsen J. Reconstruction of genome-scale active metabolic networks for 69 human cell types and 16 cancer types using INIT. PLoS Comput Biol 2012; 8: E1002518.
105. [105] Uhlen M, Oksvold P, Fagerberg L, et al. Towards a knowledgebased Human Protein Atlas. Nat Biotechnol 2010; 28: 1248-50.
106. [106] Wang Y, Eddy JA, Price ND. Reconstruction of genome-scale metabolic models for 126 human tissues using mCADRE. BMC Syst Biol 2012; 6: 153.
107. [107] Rokhlenko O, Shlomi T, Sharan R, Ruppin E, Pinter RY. Constraint-based functional similarity of metabolic genes: Going beyond network topology. Bioinformatics 2007; 23: 2139-46.
108. [108] Raman K, Chandra N. Flux balance analysis of biological systems: Applications and challenges. Brief Bioinform 2009; 10: 435-49.
109. [109] Li L, Zhou X, Ching WK, Wang P. Predicting enzyme targets for cancer drugs by profiling human Metabolic reactions in NCI-60 cell lines. BMC Bioinformatics 2010; 11: 501.
110. [110] Folger O, Jerby L, Frezza C, Gottlieb E, Ruppin E, Shlomi T. Predicting selective drug targets in cancer through metabolic networks. Mol Syst Biol 2011; 7: 501.
111. [111] Berger SI, Iyengar R. Role of systems pharmacology in understanding drug adverse events. Wiley Interdiscip Rev Syst Biol Med 2011; 3: 129-35.
112. [112] Zou J, Ji P, Zhao YL, et al. Neighbor communities in drug combination networks characterize synergistic effect. Mol Biosyst 2012; 8: 3185-96.
113. [113] Mizutani S, Pauwels E, Stoven V, Goto S, Yamanishi Y. Relating drug-protein interaction network with drug side effects. Bioinformatics 2012; 28: I522-28.
114. [114] Wang J, Li Z, Qiu C, Wang D, Cui Q. The relationship between rational drug design and drug side effects. Brief Bioinform 2012; 13: 377-82.
115. [115] Xie L, Li J, Xie L, Bourne PE. Drug discovery using chemical systems biology: Identification of the protein-ligand binding network to explain the side effects of CETP Inhibitors. PLoS Comput Biol 2009; 5: E1000387.
116. [116] Lounkine E, Keiser MJ, Whitebread S, et al. Large-scale prediction and testing of drug activity on side-effect targets. Nature 2012; 486: 361-7.
117. [117] Li Z, Wang R-S, Zhang X-S, Chen L. Detecting drug targets with minimum side effects in metabolic networks. IET Syst Biol 2009; 3: 523-33.
118. [118] Facchetti G, Zampieri M, Altafini C. Predicting and characterizing selective multiple drug treatments for metabolic diseases and cancer. BMC Syst Biol 2012; 6: 115.
119. [119] Chang RL, Xie L, Xie L, Bourne PE, Palsson BØ. Drug off-target effects predicted using structural analysis in the context of a metabolic network model. PLoS Comput Biol 2010; 6: E1000938.
120. [120] Kolaja K. Drug discovery: Computer model predicts side effects. Nature 2012; 486: 326-7.
121. [121] Kasarskis A, Yang X, Schadt E. Integrative genomics strategies to elucidate the complexity of drug response. Pharmacogenomics 2011; 12: 1695-715.
122. [122] Harper AR, Topol EJ. Pharmacogenomics in clinical practice and drug development. Nat Biotechnol 2012; 30: 1117-24.
123. [123] Atias N, Sharan R. An algorithmic framework for predicting side effects of drugs. J Comput Biol 2011; 18: 207-18.
124. [124] Kuhn M, Campillos M, Letunic I, Jensen LJ, Bork P. A side effect resource to capture phenotypic effects of drugs. Mol Syst Biol 2010; 6: 343.
125. [125] Huang L-C, Wu X, Chen JY. Predicting adverse drug reaction profiles by integrating protein interaction networks with drug structures. Proteomics 2013; 13: 313-24.
126. [126] Zhao X-M, Iskar M, Zeller G, Kuhn M, Van Noort V, Bork P. Prediction of drug combinations by integrating molecular and pharmacological data. PLoS Comput Biol 2011; 7: E1002323.
127. [127] Gottlieb A, Stein GY, Oron Y, Ruppin E, Sharan R. INDI: A computational framework for inferring drug interactions and their associated recommendations. Mol Syst Biol 2012; 8: 592.
128. [128] Gaulton A, Bellis LJ, Bento AP, et al. ChEMBL: A large-scale bioactivity database for drug discovery. Nucleic Acids Res 2012; 40: D1100-07.
129. [129] Halling-Brown MD, Bulusu KC, Patel M, Tym JE, Al-Lazikani B. canSAR: An integrated cancer public translational research and drug discovery resource. Nucleic Acids Res 2011; 40: D947-56.
130. [130] Wishart DS, Knox C, Guo AC, et al. DrugBank: A knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 2008; 36: D901-06.
131. [131] Zhu F, Shi Z, Qin C, et al. Therapeutic target database update 2012: A resource for facilitating target-oriented drug discovery. Nucleic Acids Res 2012; 40: D1128-36.
132. [132] Hecker N, Ahmed J, Von Eichborn J, et al. SuperTarget goes quantitative: Update on drug-target interactions. Nucleic Acids Res 2012; 40: D1113-17.
133. [133] Günther S, Kuhn M, Dunkel M, et al. SuperTarget and Matador: Resources for exploring drug-target relationships. Nucleic Acids Res 2008; 36: D919-22.
134. [134] Wang Y, Xiao J, Suzek TO, Zhang J, Wang J, Bryant SH. Pub-Chem: A public information system for analyzing bioactivities of small molecules. Nucleic Acids Res 2009; 37: W623-33.
135. [135] Kuhn M, Szklarczyk D, Franceschini A, Von Mering C, Jensen LJ, Bork P. STITCH 3: Zooming in on protein-chemical interactions. Nucleic Acids Res 2012; 40: D876-80.
136. [136] Taboureau O, Nielsen SK, Audouze K, et al. ChemProt: A disease chemical biology database. Nucleic Acids Res 2011; 39: D367-72.
137. [137] Burlingham BT, Widlanski TS. An intuitive look at the relationship of Ki and IC50: A more general use for the dixon plot. J Chem Educ 2003; 80: 214.
138. [138] Pagel P, Kovac S, Oesterheld M, et al. The MIPS mammalian protein-protein interaction database. Bioinformatics 2005; 21: 832-4.
139. [139] Isserlin R, El-Badrawi RA, Bader GD. The biomolecular interaction network database in PSI-MI 2.5. Database 2011; baq037.
140. [140] Vizcaíno JA, Reisinger F, Côté R, Martens L. PRIDE and “database on demand” as valuable tools for computational proteomics. Methods Mol Biol 2011; 696: 93-105.
141. [141] Aranda B, Achuthan P, Alam-Faruque Y, et al. The IntAct molecular interaction database in 2010. Nucleic Acids Res 2010; 38: D525-31.
142. [142] Ceol A, Aryamontri AC, Licata L, et al. MINT, the molecular interaction database: 2009 update. Nucleic Acids Res 2010; 38: D532-39.
143. [143] Stark C, Breitkreutz BJ, Chatr-aryamontri A, et al. The BioGRID interaction database: 2011 update. Nucleic Acids Res 2011; 39: D698-704.
144. [144] Salwinski L, Miller CS, Smith AJ, Pettit FK, Bowie JU, Eisenberg D. The database of interacting proteins: 2004 update. Nucleic Acids Res 2004; 32: D449-51.
145. [145] Prasad TSK, Goel R, Kandasamy K, et al. Human protein reference database—2009 update. Nucleic Acids Res 2009; 37: D767-72.
146. [146] Güldener U, Münsterkötter M, Oesterheld M, et al. MPact: The MIPS protein interaction resource on yeast. Nucleic Acids Res 2006; 34: D436-41.
147. [147] Wu J, Vallenius T, Ovaska K, Westermarck J, Mäkelä TP, Hautaniemi S. Integrated network analysis platform for protein-protein interactions. Nat Methods 2009; 6: 75-7.
148. [148] Cowley MJ, Pinese M, Kassahn KS, et al. PINA v2.0: Mining interactome modules. Nucleic Acids Res 2011; 40: D862-5.
149. [149] Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res 2012; 40: D109-114.
150. [150] Schellenberger J, Park J, Conrad T, Palsson B. BiGG: A biochemical genetic and genomic knowledgebase of large scale metabolic reconstructions. BMC Bioinformatics 2010; 11: 213.
151. [151] Chen B, Dong X, Jiao D, et al. Chem2Bio2RDF: A semantic framework for linking and data mining chemogenomic and systems chemical biology data. BMC Bioinformatics 2010; 11: 255.
152. [152] Eichborn J von Murgueitio MS, Dunkel M, Koerner S, Bourne PE, Preissner R. PROMISCUOUS: A database for network-based drugrepositioning. Nucleic Acids Res 2011; 39: D1060-6.
153. [153] Russ AP, Lampel S. The druggable genome: An update. Drug Discov Today 2005; 10: 1607-10.
154. [154] Meslamani J, Rognan D. Enhancing the accuracy of chemogenomic models with a three-dimensional binding site kernel. J Chem Inf Model 2011; 51: 1593-603.
155. [155] Xia J, Sun J, Jia P, Zhao Z. Do cancer proteins really interact strongly in the human protein-protein interaction network? Comput Biol Chem 2011; 35: 121-5.
156. [156] Joung JG, Kim SJ, Shin SY, Zhang BT. A probabilistic coevolutionary biclustering algorithm for discovering coherent patterns in gene expression dataset. BMC Bioinformatics 2012; 13: S12.
157. [157] Hassane DC, Guzman ML, Corbett C, et al. Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood 2008; 111: 5654-62.
158. [158] Kim TM, Ha SA, Kim HK, et al. Gene expression signatures associated with the in vitro resistance to two tyrosine kinase inhibitors, nilotinib and imatinib. Blood Cancer J 2011; 1: E32.
159. [159] Ma H, Goryanin I. Human metabolic network reconstruction and its impact on drug discovery and development. Drug Discov Today 2008; 13: 402-8.
160. [160] Borisy AA, Elliott PJ, Hurst NW, et al. Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci USA 2003; 100: 7977-82.
161. [161] Calzolari D, Bruschi S, Coquin L, et al. Search algorithms as a framework for the optimization of drug combinations. PLoS Comput Biol 2008; 4: E1000249.
162. [162] Vazquez A. Optimal drug combinations and minimal hitting sets. BMC Syst Biol 2009; 3: 81.
163. [163] Small BG, McColl BW, Allmendinger R, et al. Efficient discovery of anti-inflammatory small-molecule combinations using evolutionary computing. Nat Chem Biol 2011; 7: 902-8.
164. [164] Wong PK, Yu F, Shahangian A, Cheng G, Sun R, Ho CM. Closedloop control of cellular functions using combinatory drugs guided by a stochastic search algorithm. Proc Natl Acad Sci USA 2008; 105: 5105-10.
165. [165] Andrusiak K, Piotrowski JS, Boone C. Chemical-genomic profiling: Systematic analysis of the cellular targets of bioactive molecules. Bioorg Med Chem 2012; 20: 1952-60.
166. [166] Tan X, Hu L, Iii LJL, et al. Systematic identification of synergistic drug pairs targeting HIV. Nat Biotechnol 2012; 30: 1125-30.
167. [167] Collins SR, Schuldiner M, Krogan NJ, Weissman JS. A strategy for extracting and analyzing large-scale quantitative epistatic interaction data. Genome Biol 2006; 7: R63.
168. [168] Eronen V-P, Lindén RO, Lindroos A, Kanerva M, Aittokallio T. Genome-wide scoring of positive and negative epistasis through decomposition of quantitative genetic interaction fitness matrices. PLoS ONE 2010; 5: E11611.
169. [169] Lehár J, Krueger A, Zimmermann G, Borisy A. High-order combination effects and biological robustness. Mol Syst Biol 2008; 4: 215.
170. [170] Lehár J, Zimmermann GR, Krueger AS, et al. Chemical combination effects predict connectivity in biological systems. Mol Syst Biol 2007; 3: 80.
171. [171] Cokol M, Chua HN, Tasan M, et al. Systematic exploration of synergistic drug pairs. Mol Syst Biol 2011; 7: 544.
172. [172] Li S, Zhang B, Zhang N. Network target for screening synergistic drug combinations with application to traditional Chinese medicine. BMC Syst Biol 2011; 5: S10.
173. [173] Yan H, Zhang B, Li S, Zhao Q. A formal model for analyzing drug combination effects and its application in TNF-α-induced NFκB pathway. BMC Syst Biol. 2010; 4: 50.
174. [174] Peifer M, Weiss J, Sos ML, et al. Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling. PLoS ONE 2010; 5: E8919.
175. [175] Lopez AM, Pegram MD, Slamon DJ, Landaw EM. A model-based approach for assessing in vivo combination therapy interactions. Proc Natl Acad Sci USA 1999; 96: 13023-8.
176. [176] Nelander S, Wang W, Nilsson B, et al. Models from experiments: Combinatorial drug perturbations of cancer cells. Mol Syst Biol 2008; 4: 216.
177. [177] Iadevaia S, Lu Y, Morales FC, Mills GB, Ram PT. Identification of optimal drug combinations targeting cellular networks: Integrating phospho-proteomics and computational network analysis. Cancer Res 2010; 70: 6704-14.
178. [178] Saez-Rodriguez J, Alexopoulos LG, Zhang M, Morris MK, Lauffenburger DA, Sorger PK. Comparing signaling networks between normal and transformed hepatocytes using discrete logical models. Cancer Res 2011; 71: 5400-11.